TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Transcranial Treatments in Eating Disorders

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Anorexia Nervosa subjects:~* Meets DSM-5 criteria for anorexia nervosa (AN) either binge-eating/purging type or restricting-type:~* Intense fear of gaining weight or becoming fat, even though underweight.~* The ability to undergo an MRI, fMRI or other similar procedure requiring spending time in an enclosed space~* Bulimia Nervosa subjects:~* Meet DSM-5 criteria for bulimia nervosa (BN):~* Self-induced vomiting; misuse of laxatives, diuretics, enemas, medication, fasting, excessive exercise.~Exclusion Criteria:~* Electrolyte, blood count or kidney or liver function abnormalities.~* No symptoms of alcohol or other substance abuse or dependence in the past 3 months,~* No previous or current organic brain syndromes, dementia, psychotic disorders, somatization disorders, or conversion disorder, head trauma, indication of mental retardation or pervasive developmental disorder.~* No antipsychotics, tricyclic antidepressants or Wellbutrin or other medication that may lower the seizure threshold.~* Claustrophobia.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- TMS Treatment Group (Type: EXPERIMENTAL): 15 sessions active Transcranial magnetic stimulation (TMS) treatment
- TMS Sham Group (Type: SHAM_COMPARATOR): 15 sessions sham Transcranial magnetic stimulation (TMS) treatment
- tDCS Treatment Group (Type: EXPERIMENTAL): 15 sessions active Transcranial direct current stimulation (tDCS) treatment
- tDCS Sham Group (Type: SHAM_COMPARATOR): 15 sessions sham Transcranial direct current stimulation (tDCS) treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Inspire® Upper Airway Stimulation System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Meet the requirements per current CE Mark labeling~2. Willing and capable to have stimulation hardware permanently implanted, and to use the patient remote to activate the stimulation~3. Willing and capable to return for all follow-up visits and conduct sleep studies at home, including the evaluation procedures and filling out questionnaires~4. Willing and capable of providing informed consent~Exclusion Criteria:~1. Do not meet any contraindications per current CE Mark labeling~2. Body Mass Index (BMI) of \> 35~3. Central + mixed apneas \> 25% of the total apnea-hypopnea index (AHI)~4. Any chronic medical illness or condition that contraindicates a surgical procedure under general anesthesia, as judged by the clinical study Investigator~5. Has a terminal illness with life expectancy \< 12 months~6. Active psychiatric disease (psychotic illness, major depression, or acute anxiety attacks) which prevents subject compliance with the requirements of the investigational study testing~7. Any other reason the investigator deems subject is unfit for participation in the study

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Inspire® (UAS) System (Type: OTHER): This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: InSpace™ System in Comparison to Best Repair of Massive Rotator Cuff Tear.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Age 40 or older.~* Positive diagnostic imaging of the affected shoulder indicating full thickness Massive RCT involving more than one tendon.~* Persistent pain and functional disability of the affected shoulder for at least 3 months.~Main Exclusion Criteria :~* Known allergy to the balloon material (copolymer of PLA and -θ-caprolactone).~* Evidence of significant osteoarthritis or cartilage damage in the shoulder~* Evidence of gleno-humeral instability~* Previous surgery of the shoulder in the past 2 years, excluding diagnostic arthroscopy~* Evidence of major joint trauma, infection, or necrosis in the shoulder~* Partial-thickness tears of the rotator cuff

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Best Repair of torn Rotator Cuff (Type: SHAM_COMPARATOR): Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
- InSpace™ system (Type: ACTIVE_COMPARATOR): Subjects will undergo surgical intervention (usually arthroscopy or mini invasive) of debridement, acromioplasty if deemed necessary with or without long head of biceps tenotomy, and placement of the InSpace™ system.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of probable AD, with MMSE score of 16-26, and brain MRI consistent with the diagnosis of AD~* Concurrent use of cholinesterase inhibitor or memantine allowed, if stable.~* Caregiver will participate and be able to attend clinic visits with patient.~Exclusion Criteria:~* Significant neurological disease other than AD, or a major psychiatric disorder~* Contraindication to undergo brain MRI (e.g., pacemaker, CSF shunt, or foreign metal objects in the body)~* Woman of childbearing potential

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 88 Years
- Healthy Volunteers: f

Study Arms:
- Bapineuzumab 0.5 mg/kg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Ursodeoxycholic Acid in Treatment of Gallstones in Hemolytic Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of a hemolytic disorder including spherocytosis, G6PD deficiency, thalassemia or sickle cell disease.~2. Patients with cholelithiasis or bile sludge.~3. Age greater than or equal to 4 years.~4. Ability to consent to and participate in the study and follow study procedures.~Exclusion Criteria:~1. Previous splenectomy (complete or partial)~2. Evidence of hemolytic crisis at the time of research enrollment~3. Patients with highly symptomatic gallstones who have planned surgical intervention~4. Known allergy or intolerance to UDCA~5. Existence of concurrent hepatic disease~6. Any other laboratory or clinical condition that the investigator considers clinically significant that could impact the outcome of the study or the safety of the patient.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Label (Type: EXPERIMENTAL): 32 patients with hemolytic disorders meeting the inclusion and exclusion criteria will be commenced on Ursodeoxycholic acid (UDCA).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* gonadotroph adenoma~Exclusion Criteria:~* visual impairment attributable to the adenoma~* radiation therapy~* active gallbladder disease~* uncontrolled diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pasireotide LAR (Type: EXPERIMENTAL): 80 mg IM once monthly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of InFat™ Product on Stool Biochemistry and Stool Characteristics in Formula-fed Term Chinese Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Term infants: gestation 37-40 weeks~* Birth weight 2500-4000 g~* Apparent good health~* The infant is a product of normal pregnancy and delivery.~Exclusion Criteria:~* Any maternal disease (psychological or disabled) or socioeconomic problems that may interfere with the mother's ability to take care of her infant~* Major congenital abnormality or chromosomal disorder with a clinical significance that can be detected at birth, clinically significant~* Disease requiring mechanical ventilation or medication treatment at the first week (not including photo treatment for infantile hepatitis)~* Born with a 5- or 10-minute Apgar score \<7~* Any suspected or known metabolic or physical limitations interfering with feeding or normal metabolism (require a special formula)~* Breast-feeding for a week or over.~* Any other reason that, in the opinion of the investigator, prevents the subject from participating in the study.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 8 Days
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Infant formula with InFat™ oil(containing \~49% of C16:0 at sn-2 position).
- 2 (Type: PLACEBO_COMPARATOR): Standard vegetable oil based infant formula

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 18 and 50 years, inclusive.~* Acute symptomatic exacerbation of MS present for great than 24 hours and less than or equal to 7 days at entry with new or worsening symptoms, and with signs referable to the symptoms; in the absence of a fever or active infection.~* Diagnosis of a relapsing form of multiple sclerosis before randomization as determined by Poser or McDonald Criteria.~* Expanded disability status scale (EDSS) score between 2 and 6.5, inclusive at entry.~* Episodes include study neurologist or neuro-ophthalmologist diagnosed: acute optic neuritis, cerebellar, brainstem dysfunction, myelitis, focal cerebral, and/or definitive focal sensory dysfunction.~* New objective clinical finding other than a sensory exacerbation, or bowel/bladder signs alone. Sensory deficits alone will not qualify except for optic neuritis.~* Subjects may continue on their current immunomodulating therapy (such as interferons or glatiramer acetate) throughout the course of the study. Women who become pregnant after the 5-day treatment of steroids should discontinue immunomodulatory treatment.~* Understand and sign written informed consent prior to any testing under this protocol, including screening tests and evaluations that are not considered part of the subject's routine care.~Exclusion Criteria:~* Any patients treated with systemic corticosteroid use within one month of the index episode at screening.~* Prior use of immunosuppressive treatments within 90 days of index episode (mitoxantrone, azathioprine, IVIg) or plasmapheresis.~* Any patient who is pregnant or breastfeeding.~* Unable to perform the Multiple Sclerosis Functional Composite consisting of: Timed 25-Foot Walk, 9-Hole Peg Test, and Paced Auditory Serial Addition Test (3 second).~* Peripheral or cranial neuropathy as sole problem of acute episode.~* History of any significant cardiac, gastrointestinal, hepatic, pulmonary, or renal disease; immune deficiency; or other medical conditions that would preclude corticosteroid therapy.~* Primary Progressive Multiple Sclerosis (PPMS).~* Previous participation in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- megadose oral methylprednisolone (Type: EXPERIMENTAL): 1400 mg qd/5 days
- IV methylprednisolone (Type: EXPERIMENTAL): 1000 mg/qd/5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant successfully completes 96 weeks of treatment in Study 4658-102.~Exclusion Criteria:~* Participant has a prior or ongoing medical condition that, in the Investigator's opinion, could adversely affect the safety of the participant, or make it unlikely that the course of treatment or follow-up would be completed, or impair the assessment of study results.~Other inclusion/exclusion criteria apply.

- Gender: MALE
- Minimum Age: 2 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Eteplirsen (Type: EXPERIMENTAL): Participants will receive eteplirsen via IV infusions, once weekly, for up to 284 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Motor Imagery in Rehabilitation After a Distal Radius Fracture

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* female patients~* non-comminutive distal radius fracture~* 45 to 75 years of age~Exclusion Criteria:~* distal radius fracture caused by HET~* comorbidities possibly influencing wrist function~* comorbidities possibly influencing motor imagery ability~* score higher than 72 on the Vividness of Motor Imagery Questionnaire

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Patients allocated to the control group only receive standard treatment.
- Motor imagery (Type: EXPERIMENTAL): Patients allocated to this arm perform kinesthetic motor imagery during the immobilisation period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Feeding Infant Formula Containing Prebiotics and/or Probiotics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Singleton, 10-14 days of age at registration/randomization~* Term infant with birth weight of 2500 grams or more from a vaginal birth~* Formula feeding infants must be on formula for at least 3 days~* Human milk fed infants must have received mother's own breast milk from 1 day of age to study registration and mother has intention to exclusively provide mother's own breast milk for the duration of the study~* Signed informed consent~Exclusion Criteria:~* History of underlying metabolic or chronic disease or immune compromised~* Feeding difficulties or formula intolerance

- Gender: ALL
- Minimum Age: 10 Days
- Maximum Age: 14 Days
- Healthy Volunteers: t

Study Arms:
- Control: Cow milk-based infant formula (Type: ACTIVE_COMPARATOR): Cow milk-based infant formula
- Experimental 1: Cow milk-based infant formula (Type: EXPERIMENTAL): Cow milk-based infant formula with prebiotics
- Experimental 2: Cow milk-based infant formula (Type: EXPERIMENTAL): Cow milk-based infant formula with probiotics
- Experimental 3: Cow milk-based infant formula (Type: EXPERIMENTAL): Cow milk-based infant formula with prebiotics and probiotics
- Human Milk Reference (Type: NO_INTERVENTION): Human Milk Reference

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Steroid Administration for Articular Fractures of the Elbow (SAFE Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~• All adults ≥18 years old with an isolated, intra-articular traumatic elbow fracture to be treated at Vanderbilt University Medical Center with operative intervention and a standardized post-operative rehab protocol.~* Intra-articular elbow fracture defined as:~  * Distal humerus~ * Proximal ulna~ * Radial head fracture~ * Combination fracture of two or more of the above~* Radiographs present confirming intra-articular injury~Exclusion Criteria~* Patients with bilateral elbow fractures~* Patients with an altered mental status~* Pregnant~* Allergy or contra-indication to glucocorticoid administration~* Type 1 or Type 2 diabetes~* Pre-injury limitation in elbow range or motion (patient reported)~* Unable to provide consent for themselves

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Glucocorticoid) (Type: EXPERIMENTAL): Patients will receive a single intraoperative dose of 10mg of intravenous dexamethasone. Following surgery, the participant will be provided with a 1) six-day oral methylprednisolone taper course.
- Control Arm (Placebo) (Type: PLACEBO_COMPARATOR): Patients will receive a single intraoperative dose of 10 mg of saline. Following surgery, the participant will be provided with a six-day placebo course.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Delayed Manipulation After Xiaflex Treatment in Subjects With Dupuytren's Contracture

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects (\> 18 years) of either gender with an metacarpophalangeal joint contracture and a palpable cord of \> 20 degrees of a digit (excluding the thumb) due to Dupuytren's contracture~Exclusion Criteria:~* Any subject who has had prior surgical, percutaneous needle aponeurotomy or Xiaflex treatment for Dupuytren's contracture.~* Any subject using anti-coagulant therapy other than low dose aspirin (up to 150mg/day).~* Any subject in the opinion of the MD investigators with chronic, severe or terminal medical illness which would make them unsuitable for study participation.~* Any subject with known allergy to Xiaflex (Clostridial collagenase).~* Any subject who cannot conform to the study visit schedule

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Day 1 manipulation (Type: ACTIVE_COMPARATOR): Finger manipulation one day following Clostridial collagenase injectable
- Day 2 manipulation (Type: ACTIVE_COMPARATOR): Finger manipulation two days following Clostridial collagenase injectable
- Day 4 manipulation (Type: ACTIVE_COMPARATOR): Finger manipulation four days following Clostridial collagenase injectable

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cervical Cerclage Position Throughout the Pregnancy.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women that have a cervical cerclage placed during pregnancy at the investigator's medical center.~Exclusion Criteria:~* Women that do not require cervical cerclage.~* Women that had a cervical cerclage placed at a different medical center.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 44 Years
- Healthy Volunteers: f

Study Arms:
- Cervical cerclage (Type: EXPERIMENTAL): Women with a poor obstetric history that require cervical cerclage in order to avoid late abortion/early delivery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues